caa a22 4500 606235140 CHVBK 20210128101241.0 cr unu---uuuuu 210128e20150101xx s 000 0 eng 10.1007/s11010-014-2216-y doi (NATIONALLICENCE)springer-10.1007/s11010-014-2216-y Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line [Elektronische Daten] [Rafał Krętowski, Anna Stypułkowska, Marzanna Cechowska-Pasko] The inhibition of the 26S proteasome evokes endoplasmic reticulum stress, which has been shown to be implicated in the antitumoral effects of proteasome inhibitors. The cellular and molecular effects of the proteasome inhibitor—bortezomib—on human colon cancer cells are as yet poorly characterized. Bortezomib selectively induces apoptosis in some cancer cells. However, the nature of its selectivity remains unknown. Previously, we demonstrated that, in contrast to normal fibroblasts, bortezomib treatment evoked strong effect on apoptosis of breast cancer cells incubated in hypoxic and normoxic conditions. The study presented here provides novel information on the cellular effects of bortezomib inDLD-1 colon cancer cells line. We observe twofold higher percentage of apoptotic cells incubated for 48h with 25 and 50nmol/l of bortezomib in hypoxic conditions and four-, fivefold increase in normoxic conditions in comparison to control cells, incubated without bortezomib. It is of interest that bortezomib evokes strong effect on necrosis of DLD-1colon cancer cell line. We observe the sixfold increase in necrosis of DLD-1 cells incubated with 25 or 50nmol/l of bortezomib for 48h in hypoxia and fourfold increase in normoxic conditions in comparison to adequate controls. We suggest that bortezomib may be candidates for further evaluation as chemotherapeutic agents for human colon cancer. The Author(s), 2014 Apoptosis nationallicence Bortezomib nationallicence DLD-1 nationallicence Necrosis nationallicence ORP150 nationallicence NF-κB nationallicence Krętowski Rafał Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222, Bialystok, Poland aut Stypułkowska Anna Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222, Bialystok, Poland aut Cechowska-Pasko Marzanna Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222, Bialystok, Poland aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 398/1-2(2015-01-01), 165-173 0300-8177 398:1-2<165 2015 398 11010 https://doi.org/10.1007/s11010-014-2216-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-014-2216-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Krętowski Rafał Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222, Bialystok, Poland aut NATIONALLICENCE 700 1- Stypułkowska Anna Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222, Bialystok, Poland aut NATIONALLICENCE 700 1- Cechowska-Pasko Marzanna Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222, Bialystok, Poland aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 398/1-2(2015-01-01), 165-173 0300-8177 398:1-2<165 2015 398 11010